WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsHaemonetics Corporation (HAE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 1465% more annual revenue ($20.63B vs $1.32B). HAE leads profitability with a 13.3% profit margin vs 10.1%. HAE appears more attractively valued with a PEG of 0.90. HAE earns a higher WallStSmart Score of 67/100 (B-).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

HAE

Strong Buy

67

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 10.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued
HAEUndervalued (+66.2%)

Margin of Safety

+66.2%

Fair Value

$169.88

Current Price

$55.93

$113.95 discount

UndervaluedFair: $169.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

HAE5 strengths · Avg: 8.0/10
PEG RatioValuation
0.908/10

Growing faster than its price suggests

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

EPS GrowthGrowth
28.4%8/10

Earnings expanding 28.4% YoY

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

HAE3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.574/10

Distress zone — elevated risk

Debt/EquityHealth
1.343/10

Elevated debt levels

Revenue GrowthGrowth
-2.7%2/10

Revenue declined 2.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : HAE

The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.90 suggests the stock is reasonably priced for its growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : HAE

The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.

Key Dynamics to Monitor

GEHC profiles as a value stock while HAE is a declining play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

HAE scores higher overall (67/100 vs 60/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Haemonetics Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?